These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 3675956)

  • 1. Effects of 25(OH)-vitamin D3 in hypocalcemic patients on chronic hemodialysis.
    Kronfol NO; Hersh WR; Barakat MM
    ASAIO Trans; 1987; 33(3):289-92. PubMed ID: 3675956
    [No Abstract]   [Full Text] [Related]  

  • 2. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
    Lee SH; Huang TS; Hsieh SJ
    Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypocalcemia following bilateral nephrectomy.
    Cheigh JS; Rubin AL; Stenzel KH; Whitsell JC
    Urology; 1973 Aug; 2(2):121-4. PubMed ID: 4769514
    [No Abstract]   [Full Text] [Related]  

  • 4. Improvement in left ventricular function during treatment of hemodialysis patients with 25-OHD3.
    Coratelli P; Petrarulo F; Buongiorno E; Giannattasio M; Antonelli G; Amerio A
    Contrib Nephrol; 1984; 41():433-7. PubMed ID: 6549286
    [No Abstract]   [Full Text] [Related]  

  • 5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biochemical changes in patients with chronic renal insufficiency during hemodialysis depending on whether or not they received 25-(OH)D3].
    Rico H; Naranjo P; Paniagua MC; Cordero M; Bordiu E; Charro A
    Rev Clin Esp; 1982 Oct; 167(1):45-7. PubMed ID: 7178586
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of hemodialysis bone disease with 24,25-(OH)2D3 and 1,25-(OH)2D3 alone or in combination.
    Dunstan CR; Hills E; Norman AW; Bishop JE; Mayer E; Wong SY; Eade Y; Johnson JR; George CR; Collett P
    Miner Electrolyte Metab; 1985; 11(6):358-68. PubMed ID: 3877862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
    Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
    Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
    Lindberg J; Martin KJ; González EA; Acchiardo SR; Valdin JR; Soltanek C
    Clin Nephrol; 2001 Oct; 56(4):315-23. PubMed ID: 11680662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of parathyroid function in patients with a short history of hemodialysis.
    Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
    Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Course and significance of various biochemical parameters in 1,25-dihydroxyvitamin D3 therapy of uremic osteodystrophy].
    Giachino G; Giacchino F; Basolo B; Giraudo G; Boero R; Bancale E; Nigra M; Garetto A; Jeantet A; Piccoli G
    Arch Sci Med (Torino); 1983; 140(3):259-66. PubMed ID: 6689545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of calcitriol in the control of plasma calcium after parathyroidectomy. A placebo-controlled, double-blind study in chronic hemodialysis patients.
    Clair F; Leenhardt L; Bourdeau A; Zingraff J; Robert D; Dubost C; Sachs EF; Drüeke T
    Nephron; 1987; 46(1):18-22. PubMed ID: 3299116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality risk among hemodialysis patients receiving different vitamin D analogs.
    Tentori F; Hunt WC; Stidley CA; Rohrscheib MR; Bedrick EJ; Meyer KB; Johnson HK; Zager PG;
    Kidney Int; 2006 Nov; 70(10):1858-65. PubMed ID: 17021609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1,25-Dihydroxycholecalciferol deficiency: the probable cause of hypocalcemia and metabolic bone disease in pseudohypoparathyroidism.
    Drezner MK; Neelon FA; Haussler M; McPherson HT; Lebovitz HE
    J Clin Endocrinol Metab; 1976 Apr; 42(4):621-8. PubMed ID: 1083395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Parathyroidectomy in secondary hyperparathyroidism in chronic uremic patients under dialysis treatment. Development of the surgical strategy].
    Zucchi C
    Minerva Med; 1985 Mar; 76(9-10):397-401. PubMed ID: 3982697
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of oral calcitriol pulse therapy on the lipid, calcium, and glucose homeostasis of hemodialysis-patients: its safety in a combination with oral calcium carbonate.
    Khajehdehi P; Taheri S
    J Ren Nutr; 2003 Apr; 13(2):78-83. PubMed ID: 12671829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Parathyroid hormone values in patients on chronic dialysis treatment].
    Mushmov D; Milkov V; Kiriakov Z; Zakharieva B
    Vutr Boles; 1986; 25(3):59-62. PubMed ID: 3765580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient Education. Bone disease: preparing for your parathyroidectomy.
    McCall E; Keinholz M
    J Ren Nutr; 2013 Sep; 23(5):e101-2. PubMed ID: 23973100
    [No Abstract]   [Full Text] [Related]  

  • 19. Red blood cell deformability and secondary hyperparathyroidism in uremic patients on maintenance hemodialysis.
    Docci D; Turci F; Salvi P; Pretolani E
    Artif Organs; 1984 May; 8(2):141-4. PubMed ID: 6547327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transient congenital idiopathic hypoparathyroidism.
    Fanconi A; Prader A
    Helv Paediatr Acta; 1967 Aug; 22(4):342-59. PubMed ID: 5602969
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.